PATENT CLAIM ANALYSIS

Application Number: 16059121
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-07
Patent Classification: ["514", "04400A"]

Abstract:
The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).

Claim (Index 1):
An isolated nucleic acid comprising:\n (a) a first region that encodes one or more first miRNAs comprising a nucleic acid having sufficient sequence complementary with an endogenous mRNA of a subject to hybridize with and inhibit expression of the endogenous mRNA, wherein the endogenous mRNA encodes a first protein; and (b) a second region encoding an exogenous mRNA that encodes a second protein, wherein the second protein has an amino acid sequence that is at least 85% identical to the first protein, wherein the one or more first miRNAs do not comprise a nucleic acid having sufficient sequence complementary to hybridize with and inhibit expression of the exogenous mRNA, and wherein the first region is positioned within an untranslated portion of the second region.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 96.0
- Lexical Diversity: 1.08
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14113118', '15098833', '13642719', '14445670', '15705909']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7507436205407898
- 35 USC 102 Novelty (BERT): 0.7165928705385586
- Combined Prediction Score: 0.7473285455405667
- Mean Citation Score: 539.9870999999998
- Max Citation Score: 791.0799599999997
- Similarity Product: 745.5707913731145

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test